BioWorld - Wednesday, February 4, 2026

BioWorld Science

June 9, 2021

View Archived Issues

Nippon Shinyaku patents muscarinic acetylcholine M3 receptor positive allosteric modulators

Read More

New mucolipin-1 activators identified at Libra Therapeutics

Read More

Suzhou Zelgen Biosciences divulges Toll-like receptor 7/8 agonists

Read More

New PDE6C and PDE5A inhibitors discovered at ILDONG Pharmaceutical

Read More

Yuhan Corp. and Green Cross Corp. present ceramide glucosyltransferase inhibitors

Read More

GS-3583 well tolerated, expands dendritic cells in healthy subjects

Read More

First-in-human study shows anti-ICOS KY-1044 well tolerated alone and with atezolizumab

Read More

Aivita presents phase II data for its personalized GBM vaccine candidate, AV-GBM-1

Read More

Phase Ib data indicate ST-617 can reduce severity of OM in patients receiving chemoradiation

Read More

Promising interim phase I and II data for BION-1301 in patients with IgA nephropathy

Read More

Early phase II results presented for ponatinib plus blinatumomab combination in Ph+ ALL patients

Read More

Stress sensor DJ-1 can heighten or dampen inflammation

Read More

DZD-9008 shows antitumor activity in NSCLC patients with EGFR exon20 insertion mutations

Read More

FDA approves IND for first-in-human study of CPI-300 in advanced tumors

Read More

Icosavax begins dosing in phase I/II trial of IVX-411 for COVID-19

Read More

Arena begins phase II study of temanogrel for coronary microvascular obstruction

Read More

PDS-0101, M-9241 and bintrafusp alfa combination in advanced HPV16-positive malignancies

Read More

Aclaris reports topline phase IIa data on ATI-1777 in moderate to severe atopic dermatitis

Read More

Cardiff Oncology initiates phase II trial of onvansertib for metastatic pancreatic cancer

Read More

A new selective, reversible BTK inhibitor bearing an imidazo[4,5-b]pyridine scaffold

Read More

Intracellular nanobody delivery for the treatment of intracellular Ehrlichia chaffeensis infection

Read More